Physician profile
Tel M Todd
NPI 1477909646
$808.25
in general payments reported to CMS, 2019-2025
12 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $75.07 · 2021: $79.45 · 2022: $155 · 2023: $62.46 · 2024: $226 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $239.60 | 2024-2025 | Infuse |
| Oyster Point Pharma, INC. | $112.60 | 2022 | |
| Glaukos Corporation | $89.66 | 2025 | Istent Infinite, Idosetr |
| Alcon Vision LLC | $86.79 | 2021-2022 | |
| Coopervision INC. | $80.00 | 2023-2024 | Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $59.63 | 2020 | |
| Lkc Technologies, INC. | $56.86 | 2024 | |
| Allergan, INC. | $22.87 | 2022 | |
| Dompe US, INC. | $17.17 | 2024 | Oxervate |
| Biotissue Holdings INC. | $15.63 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.44 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tel Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.